Fox Chase Researcher Erica Golemis Appointed Senior Editor for eLife

Erica Golemis, PhD, deputy chief science officer and co-leader of the Molecular Therapeutics Program at Fox Chase.
Erica Golemis, PhD, deputy chief science officer and co-leader of the Molecular Therapeutics Program at Fox Chase.

PHILADELPHIA (October 22, 2020)—Erica Golemis, PhD, deputy chief science officer and co-leader of the Molecular Therapeutics research program at Fox Chase Cancer Center, was recently appointed senior editor at eLife, an open-access, peer-reviewed journal.

The goal of eLife is to change research communication through improvements in science publishing, technology, and research culture. It is supported by the Howard Hughes Medical Institute and other leading research organizations.

The journal covers a wide range of topics, including biochemistry and chemical biology, cancer biology, cell biology, chromosomes and gene expression, developmental biology, and much more.

“I’ve read articles in eLife for years and have been impressed by their scientific creativity, impact, and rigor. As they’ve expanded their focus on cancer research, they were recruiting more editors and invited me to join,” said Golemis. “It’s a wonderful journal and I’m excited to be part of it.”

According to eLife, the journal seeks to make peer review faster, fairer, and more open by reducing revision rounds and requesting additional experiments only when necessary. All research papers published by eLifeare accompanied by the decision letter and author response.

“It’s a journal where the senior staff are all practicing scientists who are very active in their fields. I must say, having gotten involved with it, I am stunned at the level of engagement editors have,” Golemis said.

“Every single paper that comes through the door, editors at eLifespend substantial time discussing. There’s usually at least two or three editors who weigh in on each manuscript, and they try to be very fair and offer constructive feedback to the authors. This effort shows in the quality of work they publish.”

Golemis received her doctorate in biology from the Massachusetts Institute of Technology and then performed postdoctoral work at Harvard Medical School. She has worked at Fox Chase since 1993, running an independent lab that focuses on defining the changes in cell signaling that occur as tumors initiate, progress, and develop resistance to drugs.

Golemis holds the William Wikoff Smith Chair in Cancer Research

, which supports an outstanding leader in the field of cancer research. She is a member of the American Society for Cell Biology and the American Association for Cancer Research, and is a fellow of the American Association for the Advancement of Science.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427